Literature DB >> 2888894

N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity.

A J Bridges1, W H Moos, D L Szotek, B K Trivedi, J A Bristol, T G Heffner, R F Bruns, D A Downs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2888894     DOI： 10.1021/jm00393a003

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  10 in total

1.  A3-adenosine receptors: design of selective ligands and therapeutic prospects.

Authors:  Kenneth A Jacobson; Hea O Kim; Suhaib M Siddiqi; Mark E Olah; Gary L Stiles; Dag K J E von Lubitz
Journal:  Drugs Future       Date:  1995-07       Impact factor: 0.148

2.  A binding site model and structure-activity relationships for the rat A3 adenosine receptor.

Authors:  P J van Galen; A H van Bergen; C Gallo-Rodriguez; N Melman; M E Olah; A P IJzerman; G L Stiles; K A Jacobson
Journal:  Mol Pharmacol       Date:  1994-06       Impact factor: 4.436

3.  Human adenosine A2a receptor (A2aAR) gene: systematic mutation screening in patients with schizophrenia.

Authors:  J Deckert; M M Nöthen; M Rietschel; D Wildenauer; B Bondy; M A Ertl; M Knapp; P R Schofield; M Albus; W Maier; P Propping
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

4.  Agonist derived molecular probes for A2 adenosine receptors.

Authors:  K A Jacobson; L K Pannell; X D Ji; M F Jarvis; M Williams; A J Hutchison; W W Barrington; G L Stiles
Journal:  J Mol Recognit       Date:  1989-12       Impact factor: 2.137

Review 5.  Novel therapeutics acting via purine receptors.

Authors:  K A Jacobson; B K Trivedi; P C Churchill; M Williams
Journal:  Biochem Pharmacol       Date:  1991-05-15       Impact factor: 5.858

Review 6.  Adenosine A1 and A2 receptors: structure--function relationships.

Authors:  P J van Galen; G L Stiles; G Michaels; K A Jacobson
Journal:  Med Res Rev       Date:  1992-09       Impact factor: 12.944

7.  Biological Evaluation of 5'-(N-Ethylcarboxamido)adenosine Analogues as Grp94-Selective Inhibitors.

Authors:  Dilip K Tosh; Christopher M Brackett; Young-Hwan Jung; Zhan-Guo Gao; Monimoy Banerjee; Brian S J Blagg; Kenneth A Jacobson
Journal:  ACS Med Chem Lett       Date:  2021-03-01       Impact factor: 4.345

8.  Structure-Activity Relationships of the Sustained Effects of Adenosine A2A Receptor Agonists Driven by Slow Dissociation Kinetics.

Authors:  J Daniel Hothersall; Dong Guo; Sunil Sarda; Robert J Sheppard; Hongming Chen; Wesley Keur; Michael J Waring; Adriaan P IJzerman; Stephen J Hill; Ian L Dale; Philip B Rawlins
Journal:  Mol Pharmacol       Date:  2016-11-01       Impact factor: 4.436

9.  Adenosine receptor prodrugs: synthesis and biological activity of derivatives of potent, A1-selective agonists.

Authors:  M C Maillard; O Nikodijević; K F LaNoue; D Berkich; X D Ji; R Bartus; K A Jacobson
Journal:  J Pharm Sci       Date:  1994-01       Impact factor: 3.534

10.  Synthesis and biological activity of a new series of N6-arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-carboxamido derivatives of adenosine-5'-N-ethyluronamide as A1 and A3 adenosine receptor agonists.

Authors:  P G Baraldi; B Cacciari; M J Pineda de Las Infantas; R Romagnoli; G Spalluto; R Volpini; S Costanzi; S Vittori; G Cristalli; N Melman; K S Park; X D Ji; K A Jacobson
Journal:  J Med Chem       Date:  1998-08-13       Impact factor: 8.039
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.